阿仑膦酸钠联合化疗对多发性骨髓瘤患者骨代谢的影响

目的:研究阿仑膦酸钠联合化疗对多发性骨髓瘤患者骨代谢的影响。方法:选取2011年4月到2014年4月我院收治的多发性骨髓瘤患者130例,按照随机数字表法将患者分为研究组和对照组,每组65例,对照组给予化疗,研究组在对照组的基础上给予阿仑膦酸钠,比较两组骨特异性碱性磷酸酶(BAP)、骨钙素(OC)、I型前胶原氨基肽(PINP)、血钙(Ca)、血磷(P)、β胶原特殊序列(β-CTx)以及碱性磷酸酶(ALP)。结果:治疗后研究组OC、PINP和BAP均显著高于治疗前和对照组,比较差异均有统计学意义(P0.05);治疗后研究组β-CTx显著低于治疗前和对照组,比较差异均有统计学意义(P0.05)。结论:阿仑膦酸钠联合化疗治疗多发性骨髓瘤患者能显著改善其的骨代谢,值得临床推广。

The Effect of Alendronate in Combination with Chemotherapy on Bone Metabolismin Patients with Multiple Myeloma

Objective:To study the effect of alendronate in combination with chemotherapy on bone metabolism in patients with multiple myeloma.Methods:130 cases with multiple myelomawho treated in our hospital from April 2011 to April 2014were selected, they were divided into the study group and the control group according to a randomnumber table, 65 cases in each group, the patients of the control group were treated with chemotherapy, the patients of the study group were given alendronate on the basis of the control group, bone-specific alkaline phosphatase (BAP), osteocalcin (OC), I procollagen amino-peptide (PINP), calcium, phosphorus, beta collagen special sequences (beta-CTx) and alkaline phosphatase of two groups were compared.Results:After treatment, the OC, PINP and BAP of the study group were significantly higher than before treatment andthe control group, the difference was statistically significant (P<0.05); The beta-CTx of the study group were significantly lower than before treatment and the control group, the difference was statistically significant (P<0.05).Conclusion:Alendronate combination with chemotherapy in treatment of multiple myeloma can significantly improve bone metabolism. It is worthy of clinical promotion.